After graduating from university, Masaki ITO worked at a city bank before joining ONO PHARMACEUTICAL CO., LTD.
Serving as General Manager of the Accounting Department and the Corporate Planning Department, he currently serves as Corporate Officer.
He was appointed as Operating Officer/President upon the establishment of the Company.
Executive Investment Director
Masakatsu KOBAYASHI, Ph.D.
Masakatsu KOBAYASHI joined ONO PHARMACEUTICAL CO., LTD. and engaged in drug discovery research. He led planning of discovery alliance with academia or startups at the UK subsidiary.
After working as Associate Director of the Corporate Planning Department, he was transferred to Godot Inc. and K-three Inc., where he was also in charge of new business of ONO PHARMACEUTICAL CO., LTD.
Senior Investment Director
After working in clinical development at Boehringer Ingelheim, Maya FUJITA was engaged in startup investment mainly in the healthcare field at INCJ, Ltd.
She was in charge of many startups such as Orphan Disease Treatment Institute (stock transfer to DAIICHI SANKYO COMPANY, LIMITED), Curadim Pharma (spin-out venture from Meiji Seika Pharma Co., Ltd.), ABEJA, Inc. (IPO), STORES, Inc. and others.
Joined ONO PHARMACEUTICAL CO., LTD.to establish this Company.
Samurai Incubate Inc. (Healthcare adviser)
Seikei University, Lecturer (part-time)
After joining ONO PHARMACEUTICAL CO., LTD., Masanori NISHIKORI engaged sales activities in the primary therapeutic area as Associate Director. After that he engaged in marketing activity in the diabetes area.
Prior to his current position, he was the Associate Director of planning and promotion of clinical research in the fields of cardiovascular and renal diseases at Medical Affairs.